| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
RAS inhibitor Abd-7 targets the RAS oncoprotein, a small GTPase that cycles between an active GTP-bound state and an inactive GDP-bound state. RAS activates downstream signaling pathways including MAPK, PI3K, and RALGDS, promoting cell proliferation and survival. By inhibiting RAS, Abd-7 would be expected to block these signaling pathways and inhibit cancer cell growth. However, the specific binding site and mechanism of inhibition have not been characterized in publicly available literature.
|
|---|---|
| ln Vitro |
Abd-7, a powerful cell reagent, inhibits the growth of cancer cells in the low micromolar range (0–20 μM; 24-48 hours) [1].
Specific in vitro activity data for RAS inhibitor Abd-7 are not available in the publicly accessible literature. As a RAS inhibitor, it would be expected to inhibit the proliferation of RAS-mutant cancer cell lines. However, without published studies, the compound's potency, selectivity, and mechanism of action remain to be characterized. |
| ln Vivo |
In vivo activity data for RAS inhibitor Abd-7 are not available in the publicly accessible literature. As a research compound, it has not been evaluated in animal models or clinical studies. Further research would be needed to determine its in vivo pharmacological profile and potential therapeutic applications.
|
| Enzyme Assay |
RAS activity assays are performed using recombinant RAS protein and appropriate substrates. GTPase activity is measured by monitoring the hydrolysis of GTP to GDP. RAS-GTP levels are measured using pull-down assays with the RAS-binding domain of effector proteins. Cellular assays measure RAS activation and downstream signaling. However, specific assay protocols for Abd-7 are not available.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: DLD-1 cells, HT1080 Cell Tested Concentrations: 0-20 μM Incubation Duration: 24-48 hrs (hours) Experimental Results: At 72 hrs (hours), the IC50 in DLD-1 was 8 μM and the IC50 in HT1080 was 10 μM (similar IC50 values were found after 48 hrs (hours)). Cellular assays for RAS inhibitor Abd-7 would employ RAS-mutant cancer cell lines. Cells would be treated with varying concentrations of the compound for 24-72 hours. Cell viability would be assessed using MTT or CellTiter-Glo assays. RAS-GTP levels would be measured by pull-down assays. Downstream signaling (p-ERK, p-AKT) would be assessed by Western blot. However, specific published protocols for Abd-7 are not available. |
| Animal Protocol |
In vivo studies for RAS inhibitor Abd-7 have not been reported. If evaluated in animal models, standard protocols for pharmacokinetic, efficacy, or toxicity studies would apply. The compound would be administered via appropriate routes at various doses, and parameters such as body weight, clinical signs, and tumor growth would be monitored.
|
| ADME/Pharmacokinetics |
RAS inhibitor Abd-7 has CAS number 2351843-48-4. It is a small molecule inhibitor of the RAS oncoprotein. Detailed physicochemical properties such as molecular weight and formula are not readily available in the public literature. The compound should be handled with appropriate laboratory safety precautions. Further characterization would be needed to determine its properties.
|
| Toxicity/Toxicokinetics |
Toxicological data for RAS inhibitor Abd-7 are not available in the publicly accessible literature. As a research compound, its toxicity profile has not been characterized. Standard laboratory safety precautions should be followed when handling the compound. Further toxicological studies would be required for any therapeutic development.
|
| References | |
| Additional Infomation |
RAS inhibitor Abd-7 is a small molecule inhibitor of the RAS oncoprotein, a key driver of many human cancers. RAS mutations are among the most common oncogenic alterations. Abd-7 is designed to inhibit RAS activity for cancer research. However, specific information about this compound's biological activity, molecular target, and pharmacological properties is not readily available in the publicly accessible literature. Further research would be needed to characterize this compound.
|
| Molecular Formula |
C23H25N3O3
|
|---|---|
| Molecular Weight |
391.46290564537
|
| Exact Mass |
391.189
|
| CAS # |
2351843-48-4
|
| PubChem CID |
134812710
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
498
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1CCOC2C=CC=C(C3C=CC(=C(N=3)OC)NC3C=CC(=CC=3)CN(C)C)C1=2
|
| InChi Key |
MJHHFDJNRRCUOB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H25N3O3/c1-26(2)15-16-7-9-17(10-8-16)24-20-12-11-19(25-23(20)27-3)18-5-4-6-21-22(18)29-14-13-28-21/h4-12,24H,13-15H2,1-3H3
|
| Chemical Name |
6-(2,3-dihydro-1,4-benzodioxin-5-yl)-N-[4-[(dimethylamino)methyl]phenyl]-2-methoxypyridin-3-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~319.32 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (5.31 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5545 mL | 12.7727 mL | 25.5454 mL | |
| 5 mM | 0.5109 mL | 2.5545 mL | 5.1091 mL | |
| 10 mM | 0.2555 mL | 1.2773 mL | 2.5545 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
